Mathers Edward T 4

What Happened

• Edward T. Mathers, a director of OnKure Therapeutics (NASDAQ: OKUR), received a derivative award on 2026-06-04 covering 7,650 shares. The Form 4 reports the acquisition price as $0.00 (transaction code A — award/grant). The filing lists the instrument as an option (footnote refers to "shares subject to the option"); no exercise price or immediate cash value is shown in the excerpt.

Key Details

• Transaction date: June 4, 2026; Form 4 filed June 8, 2026 (timely within the two-business-day filing window).
• Type: Award/grant of a derivative (option) covering 7,650 underlying shares; acquisition price reported as $0.00.
• Vesting: Per footnote, 100% of the option vests on the earlier of June 4, 2027 or the day prior to the issuer’s next annual meeting, subject to continued service.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• No related sales, tax withholding, or 10b5-1 plan referenced in the provided excerpt.

Context

• This was an equity compensation grant to a director (routine for board members). The award does not represent an immediate market purchase or sale; value, strike/ exercise price and potential future sale would determine any future market impact. If Mathers later exercises or sells shares, those transactions would be reported separately.